Gujarat Themis Biosyn
450.20
+0.80(+0.18%)
Market Cap₹4,905.60 Cr
PE Ratio110.09
IndustryHealthcare
Company Performance:
1D+0.18%
1M+7.08%
6M+49.44%
1Y+84.92%
5Y+84.92%
View Company Insightsright
Latest news about Gujarat Themis Biosyn
More news about Gujarat Themis Biosyn
20May 25
Gujarat Themis Biosyn Reports Decline in Q4 Financial Performance
Gujarat Themis Biosyn's Q4 results show a decline in key financial metrics. Revenue decreased by 10.1% to ₹377.4 crore, while net profit fell 25% to ₹120 crore compared to the previous year. EBITDA dropped 23.3% to ₹160.4 crore, with the EBITDA margin contracting to 42.5% from 49.82%. The company faces challenges across revenue, profitability, and operational efficiency.
06May 25
Gujarat Themis Biosyn Launches Commercial Production at New API Plant
Gujarat Themis Biosyn Ltd (GTBL) has commenced commercial production at its new Active Pharmaceutical Ingredient (API) plant in Gujarat. This strategic move aims to enhance the company's manufacturing capabilities and expand its market reach. The new facility is expected to strengthen GTBL's forward integration initiatives, potentially improving profit margins and supply chain control. The company is focusing on reinforcing its position in key export markets, particularly the United States and Europe. This expansion signifies GTBL's commitment to growth and innovation in the pharmaceutical sector, positioning it to meet increasing global demand for high-quality APIs.
Gujarat Themis Biosyn
450.20
+0.80
(+0.18%)
1 Year Returns:+84.92%
Industry Peers
Sun Pharmaceutical
1,691.40
(+0.33%)
Divis Laboratories
6,656.50
(-3.30%)
Cipla
1,505.70
(+0.28%)
Torrent Pharmaceuticals
3,580.00
(+0.75%)
Dr Reddys Laboratories
1,205.40
(+0.02%)
Zydus Life Science
944.10
(+0.79%)
Mankind Pharma
2,261.80
(-2.05%)
Lupin
1,971.80
(+0.83%)
Alkem Laboratories
5,668.50
(+0.44%)
Aurobindo Pharma
1,123.80
(-1.47%)